MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway

Molecular Biology Reports

Volumn 40, Issue 2, 2013, Pages 1711-1720

  Zhang, Ya Fei ^a,b   Zhang, An Ran ^a   Zhang, Bi Cheng ^b   Rao, Zhi Guo ^b   Gao, Jian Fei ^b   Lv, Mu Han ^a   Wu, Yu Yun ^a   Wang, Su Min ^a   Wang, Rong Quan ^a   Fang, Dian Chun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Anoikis; Cell cycle; Esophageal adenocarcinoma; MiR 26a; Rb1 E2F1 signaling pathway

Indexed keywords

GINSENOSIDE RB 1; MICRORNA 26A; TRANSCRIPTION FACTOR E2F1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOIKIS; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION;

3' UNTRANSLATED REGIONS; ADENOCARCINOMA; ANIMALS; ANOIKIS; BASE SEQUENCE; BINDING SITES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MICE; MICE, NUDE; MICRORNAS; NEOPLASM TRANSPLANTATION; RETINOBLASTOMA PROTEIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84878353670     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2222-7     Document Type: Article

References (40)

1. Pohl H, Sirovich B, Welch HG et al (2010) Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 19(6):1468-1470
2. Mariette C, Balon JM, Piessen G et al (2003) Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 97(7):1616-1623
3. Horbinski C, Mojesky C, Kyprianou N (2010) Live free or die: tales of homeless (cells) in cancer. Am J Pathol 177(3):1044-1052
4. Frisch SM, Screaton RA (2001) Anoikis mechanisms. Curr Opin Cell Biol 13(5):555-562
5. Simpson CD, Anyiwe K, Schimmer AD (2008) Anoikis resistance and tumor metastasis. Cancer Lett 272(2):177-185
6. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674
7. Inui M, Martello G, Piccolo S (2010) MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 11(4):252-263
8. Korpal M, Kang Y (2008) The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 5(3):115-119
9. Krichevsky AM, Gabriely G (2009) miR-21: a small multi-faceted RNA. J Cell Mol Med 13(1):39-53
10. Schafer ZT, Grassian AR, Song L et al (2009) Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461(7260):109-113
11. Gros SJ, Dohrmann T, Peldschus K et al (2010) Complementary use of fluorescence and magnetic resonance imaging of metastatic esophageal cancer in a novel orthotopic mouse model. Int J Cancer 126(11):2671-2681
12. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402-408
13. Zhang YF, Li XH, Shi YQ (2011) CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53. Oncol Rep 25(4):1091-1098
14. Dong LW, Yang GZ, Pan YF et al (2011) The oncoprotein p28(GANK) establishes a positive feedback loop in β-catenin signaling. Cell Res 21(8):1248-1261
15. Ji J, Shi J, Budhu A, Yu Z et al (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361(15):1437-1447
16. Villanueva A, Hoshida Y, Toffanin S et al (2010) New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 16(9):4688-4694
17. Ciarapica R, Russo G, Verginelli F et al (2009) Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 8(1):172-175
18. Heinzelmann J, Henning B, Sanjmyatav J et al (2011) Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 29(3):367-373
19. Kota J, Chivukula RR, O'Donnell KA et al (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6):1005-1017
20. Kim H, Huang W, Jiang X et al (2010) Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci USA 107(5):2183-2188
21. Du W, Searle JS (2009) The rb pathway and cancer therapeutics. Curr Drug Targets 10(7):581-589
22. Rogoff HA, Kowalik TF (2004) Life, death and E2F: linking proliferation control and DNA damage signaling via E2F1. Cell Cycle 3(7):845-846
23. Tanaka H, Matsumura I, Ezoe S et al (2002) E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell 9(5):1017-1029
24. Chen M, Capps C, Willerson JT (2002) E2F-1 regulates nuclear factor-kappaB activity and cell adhesion: potential antiinflammatory activity of the transcription factor E2F-1. Circulation 106(21):2707-2713
25. Hao H, Zhou HS, McMasters KM (2009) Chemosensitization of tumor cells: inactivation of nuclear factor-kappa B associated with chemosensitivity in melanoma cells after combination treatment with E2F-1 and doxorubicin. Methods Mol Biol 542:301-313
26. Hwang HC, Clurman BE (2005) Cyclin E in normal and neoplastic cell cycles. Oncogene 24(17):2776-2786
27. Ohtani K, DeGregori J, Nevins JR (1995) Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 92(26):12146-12150
28. Ak P, Levine AJ (2010) p53 and NF-κB: different strategies for responding to stress lead to a functional antagonism. FASEB J 24(10):3643-3652
29. Sander S, Bullinger L, Wirth T (2009) Repressing the repressor: a new mode of MYC action in lymphomagenesis. Cell Cycle 8(4):556-559
30. Wong CF, Tellam RL (2008) MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem 283(15):9836-9843
31. Wu Z, Yu Q (2009) E2F1-mediated apoptosis as a target of cancer therapy. Curr Mol Pharmacol 2(2):149-160
32. Mahidhara RS, Queiroz De Oliveira PE, Kohout J et al (2005) Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma. J Surg Res 123(2):302-311
33. Korotayev K, Ginsberg D (2008) Many pathways to apoptosis: E2F1 regulates splicing of apoptotic genes. Cell Death Differ 15(2):1813-1814
34. Gartel AL, Tyner AL (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1(8):639-649
35. Hiromura K, Pippin JW, Fero ML (1999) Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). J Clin Invest 103(5):597-604
36. Pucci B, Kasten M, Giordano A (2000) Cell cycle and apoptosis. Neoplasia 2(4):291-299
37. Collins NL, Reginato MJ, Paulus JK (2005) G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol 25(12):5282-5291
38. Lin Y, Bai L, Chen W, Xu S (2010) The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 14(1):45-55
39. Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749-759
40. Vachon PH (2011) Integrin signaling, cell survival, and anoikis: distinctions, differences, and differentiation. J Signal Transduct 2011:738137